HB1735: permitting treatment of certain severe illness under the right to try act.

Related law links

RSA references from bill data

• 126-Z:1 · amend

  tment of certain severe illness under the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 Right to Try Act. Amend RSA 126-Z:1 through 126-Z:4 to read as follows: 126-Z:1 Definitions. In this chapter: I. "Eligible facility" means a licensed New Hampshire institution that is operating under a Federalwide Assurance ("FWA") for the Protec

• 126-Z:3 · reference

  ce [to eligible patients pursuant to this chapter. A manufacturer may:] not approved by the United States Food and Drug Administration available to patients if the requirements of RSA 126-Z:3, III are satisfied. I-a. Pursuant to this chapter, a manufacturer may: (a) Provide [an investigational] a drug, biologic, or device to [an eligible] a patient without receiving compensation. (b) Require [an el

• 126-Z:6 · amend

  or court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 2 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

• 126-Z:8 · amend

  escreening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 3 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sa

• 151 · reference

  to this chapter. II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based primarily on the institution's participation in the treatment or use of [an investigational] a drug, biologic, or device under this chapter. III. Notwithstanding any provision of law to the contrary, a manufac

• 329 · reference

  withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi

• 329:17 · reference

  stitutional Review Board; and (b) "Off-label use" means prescribing an FDA approved drug, biologic, or device for a use not approved for that specific indication consistent with RSA 329:17, VI-b. III. "Physician" means the licensed allopathic or osteopathic physician who is providing medical care or treatment to the[ eligible] patient for the terminal or qualifying severe illness. III-a.(a) “Quali

RSAs mentioned by this document

• RSA 126-Z · RIGHT TO TRY ACT
• RSA 151 · RESIDENTIAL CARE AND HEALTH FACILITY LICENSING
• RSA 329 · PHYSICIANS AND SURGEONS
• RSA 126-Z:1 · Definitions
• RSA 126-Z:3 · Liability of Physician; Facility
• RSA 126-Z:6 · Telehealth Prescreening
• RSA 126-Z:8 · Statutory Construction
• RSA 329:17 · Disciplinary Action; Remedial Proceedings